BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Jan. 14, 2021

View Archived Issues
cancer-dna-diagnostic.png

Delfi Diagnostics reels in $100M for blood-based cancer test

Liquid biopsy startup Delfi Diagnostics Inc. scooped up $100 million in a series A round led by Orbimed Advisors LLC. The company will use the funds to grow its team of cancer researchers and machine learning experts and to validate its next-generation blood-based testing technology in prospective clinical trials. Existing investors Menlo Ventures, Samsara Biocapital, Illumina Ventures, Av8 Ventures also participated in the round, along with new investors Foresite Capital, Northpond Ventures, Cowen Healthcare Investments and Rock Springs Capital. Read More
CMS-medicare-reimbursement.png

CMS delays proposed reset of ‘reasonable and necessary’ in MCIT final rule

The Medicare Coverage of Innovative Technology (MCIT) program drew rave reviews when it was unveiled, but the associated proposal to redefine the term “reasonable and necessary” met with skepticism. The final rule includes some discussion of how private payer coverage might be leveraged to broaden the definition, but the Centers for Medicare & Medicaid Services (CMS) nonetheless punted on the question for now, promising to tackle it within a year. Read More
Percept PC device with software on phone and tablet

Medtronic kicks off ADAPT-PD study in Parkinson’s patients

Medtronic plc reported that the first patient has been enrolled in the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) study its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's disease (PD). This type of stimulation is an investigational feature of the Percept PC device that could be enabled if approved. Read More
2020 pandemic illustration

Volume up, value down, but digital tops 2020’s deal-making efforts

The volume of med-tech deals and M&As in 2020 reached impressive levels, well above 2019, primarily due to the demands of a global pandemic, although the disclosed values of those alliances fell dramatically short. Even so, the spotlight that shined on digital health and diagnostics throughout the challenging year has potentially set up the med-tech industry for an influx of attention going forward. Read More
Orthocell CEO with employees in the lab

Orthocell’s stock soars following FDA 510(k) clearance of regenerative collagen medical device

PERTH, Australia – Perth-based regenerative medicine company Orthocell Ltd. saw its shares rise 27% on the heels of its first U.S. approval for its collagen medical device for dental guided bone and soft tissue regeneration applications. “It’s an important milestone for us, and one that came quicker than I was expecting it to come,” Orthocell CEO Paul Anderson told BioWorld. The company submitted its 510(k) application to the FDA in May, and he was expecting approval by the middle of 2021. Read More

Appointments and advancements for Jan. 14, 2021

New hires and promotions in the med-tech industry, including: Cognoa, Follica, H1, Vave Health. Read More

Financings for Jan. 14, 2021

Med-tech firms raising money in public or private financings, including: Applied DNA Sciences Inc., Paige, Transenterix, Viveve Medical. Read More

In the clinic for Jan. 14, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Edap Tms. Read More

Other news to note for Jan. 14, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amalgam Rx, Avhana Health, Diasorin Molecular, Debiopharm, Euroimmun Medizinische Labordiagnostika, Kidsx, Merck, Microbot Medical, N2 Biomedical, Nucleai, Orgentec, Philips, Theradiag, Thermo Fisher Scientific, Twist Bioscience, Wellinks. Read More

Regulatory actions for Jan. 14, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Hyperfine Research, Novaerus, Perkinelmer, Perspectum. Read More

Regulatory front for Jan. 14, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: HHS examines device classification process at FDA; NIH offers NGS system for SARS-CoV-2; FDA issues pandemic policy for coagulation systems. Read More

BioWorld MedTech’s Diagnostics Extra for Jan. 14, 2021

Keeping you up to date on recent developments in diagnostics, including: Improving diagnosis of brain diseases; Predicting survival of COVID-19 patients; New causal gene for chronic kidney disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing